Rhabdomyosarcoma (RMS), a malignant tumour of early onset, is the most common type of soft-tissue sarcoma in children. Regarding histopathological criteria, RMS can be divided into two main subtypes: embryonal and alveolar (eRMS and aRMS, respectively). The majority of aRMS (80--85%) contain one of the reciprocal chromosomal translocations: t(2;13)(q35;q14) or t(1;13)(p36;q14). These translocations generate the novel fusion genes *PAX3-FOXO1* and *PAX7-FOXO1*, respectively ([@bib2]; [@bib6]). However, no characteristic translocations have been described in eRMS. Patients with metastatic RMS have very poor prognosis and more intense therapies are thus indicated. Moreover, the major cause of death in these patients is the formation of distant metastases. The cellular components that control mobility, invasiveness and metastasis in RMS remain largely unknown. The molecules responsible for these processes should be identified before the development of targeted therapies focused on reducing metastasis in this neoplasia. Recently, we described the role of Notch pathway activation in controlling the migration and invasiveness processes in RMS ([@bib29]). Similarly, the role of the Notch pathway in invasion and metastasis has also been reported in osteosarcoma ([@bib43]; [@bib42]; [@bib8]) and some adult cancers, such as colon, prostate, cervical carcinoma and glioblastoma among others ([@bib41]; [@bib25]; [@bib4]; [@bib5]).

The acquisition of invasive properties by cancer cells during tumour progression is closely linked to changes in the expression of adhesion molecules that mediate the interaction of cancer cells with their surrounding cells and extracellular matrix. During tumour progression, malignant cells typically downregulate proteins that mediate adhesion to basal membrane and neighbouring cells and, at the same time, promote the expression of adhesion molecules that facilitate dynamic interaction with extracellular matrix components ([@bib21]). A paradigmatic example of this phenomenon is the cadherin switch, frequently observed in the epithelial--mesenchymal transition of epithelial cancer cells ([@bib3]; [@bib15]). During this transition, E-cadherin expression is downregulated with concomitant enhancement of neuronal cadherin (N-cadherin) expression, which correlates with the acquisition of greater invasiveness and metastatic potential by malignant cells.

Neuronal cadherin (N-cadherin or cadherin-2) is a member of the classical type I cadherin family, which is critically involved in tissue development and maintenance. Like other classical type I cadherins, N-cadherin contains a large N-terminal extracellular domain composed of five tandem-repeated domains, a transmembrane segment and a cytoplasmatic C-terminal domain able to interact with catenins ([@bib21]). Although the mechanism by which increased N-cadherin expression promotes malignancy is not fully understood, in a subset of primary tumour cells, it is thought to promote adhesion of malignant cells to N-cadherin-expressing stromal or endothelial cells, thereby facilitating invasion and migration of tumour cells to distant sites ([@bib31]; [@bib27]). Several experiments have demonstrated that the expression of N-cadherin suffices to promote invasion and metastasis in some cancers ([@bib23]; [@bib14]; [@bib17]).

The superfamily of integrins includes several transmembrane cell adhesion proteins that bind to extracellular matrix, cell surface and soluble ligands. All integrins act as heterodimers composed of *α*- and *β*- subunits. The *α*- and *β*-polypeptidic chains are distinct with no detectable homology between them ([@bib36]). The heterodimer *α*9*β*1 has been implicated in several processes that entail dynamic interaction between cells and extracellular matrix, such as re-epithelialisation during cutaneous wound healing ([@bib34]), cell adhesion in medulloblastoma and in hematopoietic progenitor cells ([@bib10]; [@bib32]) and finally, cell migration in neoplasic and non-neoplasic cells ([@bib13]; [@bib24]).

The main objective of this work was to demonstrate the existence of a connection between Notch pathway activation and the regulation of mechanisms underlying cell motility and invasiveness in RMS. It has been previously suggested that Notch1 and Notch3 signalling may promote an upregulation of N-cadherin expression in primary melanoma ([@bib18]; [@bib38]); however, the molecular mechanisms of this possible relationship remain unclear. Moreover, as we demonstrated recently, the Notch pathway mediates RMS cell motility and invasiveness ([@bib29]). The oncogenic potential of the Notch pathway was first described in acute T-cell lymphoblastic leukaemia in the late 1980s ([@bib28]). An abnormal upregulation of the Notch pathway has also been reported in ovarian ([@bib26]), breast ([@bib12]) and other cancers ([@bib22]). With respect to paediatric malignancies, Notch signalling appears to contribute essentially to osteosarcoma metastasis ([@bib43]; [@bib42]) and proliferation ([@bib37]); Notch signalling also promotes medulloblastoma cancer stem cell survival ([@bib9]) and contributes to angiogenesis in neuroblastoma ([@bib11]). The four Notch receptors are synthesised as precursor proteins that are processed by furin-like enzymes in the *trans*-Golgi compartment. This cleavage leads to the production of a heterodimeric Notch receptor, which is further processed at the cell surface in a ligand-dependent manner by *α*- and *γ*-secretase. The *α*-secretase cleavage occurs at an extracellular site and removes the Notch ectodomain, whereas *γ*-secretase cleavage occurs in the Notch transmembrane domain, leading to the release of the intracellular Notch fragment (NICD) that translocates to the nucleus where it binds to CSL (CBF1-Su(H)-Lag1) transcription repressors, converting them into transcriptional activators. The targets of these transcription factors in vertebrates are typified by *Hes* and *Hey* genes ([@bib1]; [@bib20]). The possible demonstration of a connection between Notch signalling and the expression of adhesion molecules may shed light on the unknown molecular mechanism of the Notch-mediated invasive phenotype of RMS cells and allow us to adopt new therapeutic approaches to the fight against metastases in this neoplasia.

Materials and Methods
=====================

Cell culture, transfections and drug treatments
-----------------------------------------------

RH30, CW9019 and HTB82 RMS cell lines were grown in MEM medium with Earle\'s Salts, supplemented with 10% FCS, 2 mℳℒ-glutamine, 1 mℳ sodium pyruvate, 1 × non-essential aminoacids, 100 U ml^−1^ penicillin and 0.1 mg ml^−1^ streptomycin (all culture reagents supplied by PAA Laboratories, Haidmannweg, Austria) and maintained at 37 °C in a 5% CO~2~ water-jacketed incubator. Full-length dnMAML1, Delta and Hes1 complementary DNAs (cDNAs) were generously provided by Dr Anna Bigas (Institut Municipal d\'Investigació Mèdica, Barcelona, Spain). The full-length NICD cDNA was a kind gift from Dr Rosanna Paciucci (Institut de Recerca Hospital Vall d\'Hebron, Barcelona, Spain). All cDNAs used were cloned into a pCDNA3.1 vector, except dnMAML1 that was cloned into a pEGFP vector. All cDNA transfections were carried out in parallel with the respective empty vector as a control. Transient transfections were performed using 8 μg of plasmid DNA and FuGENE 6 transfection reagent according to the manufacturer\'s protocol (Roche, Basel, Switzerland). Transfection efficiency was approximately 70% for the three cell lines and was assessed by calculating the percentage of GFP-positive cells referred to the total of cells. Transfected cells were harvested between 48 and 72 h and processed for subsequent assays. Gamma-secretase inhibitor (GSI)-XXI (Calbiochem, San Diego, CA, USA) was diluted in DMSO and added to the culture medium for 3 days at a final concentration of 4 nℳ as previously described ([@bib29]). Control plates were supplemented with an equivalent volume of DMSO.

Complementary DNA microarrays
-----------------------------

Microarrays were carried out using the Affymetrix microarray platform and the Genechip Human Gene 1.0 ST Array; 100 ng of total RNA were used per sample. Two plates of RH30 cells previously treated with GSI were compared with their control (DMSO). Quality of total RNA was assessed by Bioanalyzer Assay (Agilent). Chips were processed on an Affymetrix GeneChip Fluidics Station 450 and Scanner 3000. Results were analysed using TMEV software ([@bib30]).

Western blotting
----------------

Cells were homogenised in lysis buffer (50 mℳ Tris-HCl, pH 7.4, 150 mℳ NaCl, 1 mℳ PMSF, 1 mℳ EDTA, 5 mg ml^−1^ aprotinin, 5 mg ml^−1^ leupeptin, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) and incubated for 4 min at 90 °C. The total protein content was measured using the DC assay kit (Bio-Rad Laboratories, Hercules, CA, USA), a 10% SDS--PAGE was performed and the resolved proteins were in turn transferred onto PVDF membranes (Bio-Rad Laboratories). Membranes were then incubated with anti-Hes1 polyclonal antibody AB5702 (Millipore, Billerica, MA, USA) diluted 1 : 200, anti-N-cadherin monoclonal antibody C2542 (Sigma, St Louis, MO, USA) diluted 1 : 1000, anti-α9-integrin monoclonal antibody clone 3E4 (Abnova, Aachen, Germany) diluted 1 : 250 and anti-Notch1 (C-20) sc-6014 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1 : 500. An anti-*α*-tubulin monoclonal antibody (Cell Signaling, Danvers, MA, USA) diluted 1 : 2000 was used as a loading control.

Immunofluorescence
------------------

Each well was plated with 3 × 10^5^ cells on 12-mm round glass coverslips pre-coated with a 4% collagen-I solution (BD Biosciences, Erembodegem, Belgium). After 24 h, cells were transfected with the appropriate plasmids as described above. After 48 h, cells were washed with PBS, fixed in 4% paraformaldehyde, incubated with 50 mℳ NH~4~Cl and permeabilised with 0.1% Triton X-100. Samples were then blocked with 5% FCS prior to incubation with the following primary antibodies: anti-Hes1 AB5702 (Millipore) diluted 1 : 50, anti-N-cadherin C2542 (Sigma) diluted 1 : 250 and anti-α9-integrin clone 3E4 (Abnova) diluted 1 : 125. Cells were then incubated with suitable secondary antibodies labelled with AlexaFluor-647 or AlexaFluor-488 (Molecular probes, Eugene, OR, USA). Nuclei were stained with 5 ng ml^−1^ of Hoechst33342 (Sigma). Fluorescence was visualised in a FV1000 confocal microscope (Olympus, Hamburg, Germany) and quantified with Olympus Fluorview software. A minimum of 100 cells obtained from random selected fields was evaluated.

Immunohistochemistry
--------------------

Patient samples (*n*=9) were obtained from the Vall d\'Hebron Hospital Pathology Department (kindly provided by Dr Nuria Toran). Paraffin-embedded tissues were sliced, deparaffinised and rehydrated, followed by antigen retrieval in 10 mℳ citrate buffer (DAKO). Endogenous peroxidase activity was quenched using 1% hydrogen peroxide. Samples were blocked and incubated with antibodies against Hes1 (AB5702, Millipore), N-cadherin (C2542, Sigma) and *α*9-integrin (3E4, Abnova), all diluted 1 : 200. After incubation with peroxidase-conjugated secondary antibody and peroxidase substrate, samples were counterstained with hematoxylin for 10 s, dehydrated and mounted. Labelling of each antibody was evaluated using a semiquantitative method regarding the percentage of positive cells (⩽25%, 26--50%, 51--75% and \>75% corresponding to a score of 1, 2, 3 and 4 respectively) and intensity of the labelling (0--3). The assigned final score (1--7) corresponds to the sum of the labelling and percentage of positive cell scores.

RNA isolation, retrotranscription and real-time PCR
---------------------------------------------------

RNA was isolated using the Quick-prep micro RNA isolation kit following the manufacturer\'s instructions (Qiagen, Valencia, CA, USA). Samples of 2 *μ*g of total RNA were reverse transcripted using random primers (Invitrogen, Carlsbad, CA, USA). The reaction mixture was incubated for 1 h at 37 °C with 200 U of Moloney murine leukaemia virus reverse transcriptase (Promega, Madison, WI, USA). A 40-cycle PCR based on the TaqMan assay (Applied Biosystems, Foster City, CA, USA) was performed to detect N-cadherin and α9-integrin (Hs00983056_m1 and Hs00979865_m1 TaqMan assays, respectively). The downstream Notch effector Hes1 (assay Hs00172878_m1) was used to assess Notch activation. The housekeeping gene *TBP* (assay Hs00172424_m1) was used as internal control. Quantification of relative levels of each mRNA analysed was performed by the method of ([@bib19]). All samples were tested in triplicate.

Fibronectin and collagen adhesion assay
---------------------------------------

A total of 3 × 10^5^ GSI-pre-treated cells per well was seeded in a 24-well plate previously coated with collagen or fibronectin. Cells were then incubated at 37 °C for 15 min (RH30), 30 min (CW9019) or 1 h (HTB82), respectively, fixed with 4% paraformaldehyde and stained with 0.2% crystal violet. Cells were then lysed in 10% acetic acid and the absorbance at 590 nm was determined as a value proportional to the number of cells adhered to the substrate. To establish the specificity of the assay for N-cadherin and α9-integrin, some wells were treated with 20 *μ*g ml^−1^ of either N-cadherin- (GC-4, Sigma) or α9-integrin-blocking antibodies (Y9A2, Chemicon International, Temecula, CA, USA). The control wells were treated with an anti-*α*-tubulin monoclonal antibody (Cell Signaling) at the same concentration, as isotypic control. All measurements were taken in triplicate.

Transwell assay
---------------

Cells were trypsinised, seeded at 10^5^ cells per well and incubated in the presence or absence of 20 *μ*g ml^−1^ of either N-cadherin or α9-integrin-blocking antibodies for 30 min on ice. Following the incubation, cells were plated in the upper chamber previously coated with BD Matrigel (BD Biosciences) in an 8-*μ*m pore-size transwell (Corning). Basal medium containing 1% FBS in the presence or absence of the aforementioned N-cadherin and *α*9-integrin-blocking antibodies was added to each well and incubated at 37 °C for 6, 12 and 48 h (for RH30, CW9019 and HTB82 cell lines, respectively). The control wells were treated with 20 *μ*g ml^−1^ anti-*α*-tubulin monoclonal antibody (Cell Signaling). Remaining cells were removed from the upper chamber with a cotton swab, and cells migrated to the lower surface were stained with 0.2% crystal violet, lysed in 10% acetic acid and the absorbance at 590 nm was determined as a value proportional to the number of cells on the lower surface of each membrane. All analyses were made in triplicate.

Wound-healing assay
-------------------

Cells were seeded on a 24-well plate (3 × 10^5^ cells per well) and incubated in the presence or absence of 20 *μ*g ml^−1^ of either N-cadherin- or *α*9-integrin-blocking antibodies as described above. The control wells were treated with 20 *μ*g ml^−1^ anti-*α*-tubulin monoclonal antibody as isotypic control (Cell Signaling). A day later, cell monolayers were scratched with a pipette tip and placed in complete growth medium with or without the suitable blocking antibody. The initial scratched areas were measured using the ImageJ software (NIH, freely available at <http://rsb.info.nih.gov/ij/>) and serial images of random selected fields were acquired until the healing of the wounds was complete. Healing velocity was calculated as a quotient between the scratched area and the time required for the wound to heal. All analyses were made in triplicate.

Chromatin immunoprecipitation (ChIP) assay
------------------------------------------

Chromatin immunoprecipitation was performed following the manufacturer\'s (Millipore) instructions using 5 *μ*g of polyclonal rabbit antibodies against Hes1 AB5702 (Millipore) and Notch1 sc-6014 (Santa Cruz Biotechnology). The same amount of rabbit immunoglobulin (IgG) was used as a control (Abcam). The co-immunoprecipitated DNAs were used for PCR to amplify N-cadherin and *α*9-integrin promoter regions. The primers used were as follows: N-cadherin promoter (forward 5′-ACCCAGAGATCAAGGAGCTG-3′ reverse 5′-CTCCACTTCCACCTCCACAT-3′) and *α*9-integrin promoter (forward 5′-GAGCTCAAAAGTGCCCTCTC-3′ reverse 5′-TGAGGGAGGAAAAAGAAGCA-3′).

Results
=======

Pharmacological inhibition of Notch signalling impairs cell adhesion in RMS cell lines
--------------------------------------------------------------------------------------

Cells treated with GSI showed a clear reduction in cell adhesiveness detected in either collagen- or fibronectin-coated plates ([Figure 1](#fig1){ref-type="fig"}). The effect produced by GSI-XXI on cell adhesiveness varied among the cell lines analysed and according to the coating of the plate surface; however, in general, treated cells showed a significant reduction in adhesion that ranged from 20 to 50% in fibronectin-coated plates ([Figure 1A](#fig1){ref-type="fig"}) and from 30 to 60% in collagen-coated plates ([Figure 1B](#fig1){ref-type="fig"}). Cell viability was assessed by flow cytometry with no substantial differences observed between GSI-treated and untreated (DMSO) cells ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). These observations fitted our hypothesis that Notch pathway may be able to regulate some of the molecular processes that lead to cell adhesion and migration. However, they did not rule out the possibility that the effects observed may have been caused by effects of the drug on other pathways or directly on cell adhesion molecules.

Pharmacological inhibition of Notch signalling significantly reduces N-cadherin and *α*9-integrin expression
------------------------------------------------------------------------------------------------------------

A cDNA microarray permitted preliminary identification of adhesion proteins downregulated under GSI treatment. Neuronal cadherin and *α*9-integrin were selected for their downregulation under GSI treatment, their significant expression (other proteins downregulated but barely expressed in control samples were ruled out) and their previously well-established involvement in cell adhesion, motility and metastasis ([Figure 2A](#fig2){ref-type="fig"}). With the aim of confirming the results obtained in the cDNA microarray, we specifically analysed the expression of the two selected genes by western blotting and qRT--PCR. Western blotting ([Figure 2B](#fig2){ref-type="fig"}) revealed a reduction in both full-length N-cadherin and the CTF2 fragment levels. The CTF1 fragment was not detected in the RMS cell lines analysed (not shown), thereby suggesting a negligible role of this isoform in RMS. Levels of *α*9-integrin were also reduced in cells treated with GSI. Levels of *β*1-integrin, the usual partner of *α*9-integrin, showed no changes (not shown). The reduction in Hes1, as a marker of effective Notch inhibition in treated cells, is also shown in [Figure 2B](#fig2){ref-type="fig"}. Similarly, mRNA levels of both N-cadherin and *α*9-integrin showed statistically significant reductions in the three cell lines, down to between 60 and 85% for N-cadherin and to 20--50% for *α*9-integrin, compared with untreated cells (100%). The mRNA expression of Hes1 was also analysed as a marker of correct Notch inhibition and showed a statistically significant reduction, as expected, in cells treated with GSI ([Figure 2C](#fig2){ref-type="fig"}). Although pharmacological Notch inhibition was not complete, reductions in N-cadherin and *α*9-integrin expressions were significant, particularly for *α*9-integrin.

Although these results confirmed the N-cadherin and *α*9-integrin reduction in cells treated with GSI, they failed to demonstrate unequivocally that the effects observed could be exclusively Notch-dependent.

Genetic modification of Notch pathway activation gives rise to a parallel regulation of N-cadherin and *α*9-integrin
--------------------------------------------------------------------------------------------------------------------

Seeking to rule out the possibility of the observed effects on cells treated with Notch inhibitors being attributable to the involvement of other pathways or to a direct effect of the drugs on N-cadherin or *α*9-integrin -- and therefore demonstrate that these effects resulted from specific Notch activation -- we genetically manipulated Notch signalling activity by transfecting constructs containing the Notch ligand Delta1 (Delta) and a dominant negative form of MAML1 (dnMAML1). Activation of the Notch pathway by transfection of Delta promotes N-cadherin and *α*9-integrin increases in both protein and mRNA levels ([Figures 3A and C](#fig3){ref-type="fig"}). Conversely, inhibition of the pathway by overexpression of the dominant negative dnMAML1 produces a parallel reduction in protein and mRNA levels of N-cadherin and *α*9-integrin ([Figures 3B and C](#fig3){ref-type="fig"}). Western blot revealed the presence of full-length N-cadherin (N-Cad FL) and the CTF2 fragment, whereas the CTF1 fragment was not detected (not shown). Both forms of N-cadherin detected (N-Cad FL and CTF2) and *α*9-integrin showed induction when the Notch pathway was activated (overexpression of Delta) and a clear reduction when repressed (overexpression of dnMAML1) ([Figures 3A and B](#fig3){ref-type="fig"}). No changes were observed in the amount of *β*1-integrin, the usual partner of *α*9-integrin (not shown).

Immunofluorescence
------------------

Fluorescent immunocytochemistry against N-cadherin revealed moderate expression of this protein in non-transfected cells ([Figures 4A and C](#fig4){ref-type="fig"}). When cells underwent overactivation of the Notch pathway (by Delta1 transfection), N-cadherin expression was significantly increased in the three cell lines analysed and conserved the localisation pattern of the endogenous protein in each cell line. The staining was localised in cytoplasm and cell membrane in RH30 and CW9019 cell lines, but more prominently in the nucleus in HTB82, which suggests a major presence of the CTF2 form in this cell line (also observed by western blot, [Figure 3](#fig3){ref-type="fig"}).

The distribution of *α*9-integrin staining was general and showed prominent nuclear and cytoplasmic staining. As in the results found with N-cadherin transfections, RMS cells transfected with Delta also showed a statistically significant increase in *α*9-integrin staining compared with controls ([Figures 4B and C](#fig4){ref-type="fig"}).

Specific anti-N-cadherin- and anti-*α*9-integrin-blocking antibodies reduce invasive properties of RMS cells
------------------------------------------------------------------------------------------------------------

Seeking to demonstrate that the role of N-cadherin and *α*9-integrin is critical for the Notch-mediated increase in RMS cell capability to migrate and invade, we performed adhesion, wound-healing and invasion assays in the presence or absence of specific blocking antibodies against these two proteins. The main aim of these experiments was to demonstrate whether inhibition of N-cadherin and/or *α*9-integrin suffices to compensate for the increases in adhesion, wound-healing and invasiveness detected in cells with constitutive Notch activation. Cells transfected with Delta or NICD showed an increase in their adhesion to fibronectin-coated plates, which could be reverted using either anti-N-cadherin- or anti-*α*9-integrin-blocking antibodies ([Figure 5A](#fig5){ref-type="fig"}). The effects of the blocking antibodies on healing velocity differed for N-cadherin and *α*9-integrin. Thus, while N-cadherin-blocking antibody gave rise to a significant reduction in healing velocity in the three cell lines analysed, the anti-*α*9-integrin-blocking antibody did not promote any significant decrease in the capability of cells to heal a wound ([Figure 5B](#fig5){ref-type="fig"}). Finally, the effects observed with both antibodies on cell invasiveness in a matrigel/transwell assay also differed ([Figure 5C](#fig5){ref-type="fig"}). Interestingly, the *α*9-integrin-blocking antibody produced marked invasiveness impairment in this assay, whereas only a very weak effect of N-cadherin-blocking antibody on invasiveness was observed.

Correlation among Hes1, N-cadherin and *α*9-integrin in RMS archival tumour samples
-----------------------------------------------------------------------------------

Patient sections were stained using antibodies against Hes1, N-cadherin and *α*9-integrin with the aim of demonstrating the correlation among these proteins observed in cultured RMS cell lines. The intensity of labelling was evaluated using a semiquantitative method as described above. The results obtained showed a correlation between the expression of Hes1 with both N-cadherin and *α*9-integrin ([Figure 6](#fig6){ref-type="fig"}). Although the number of samples was limited (*n*=9), the correlation between Hes1 and N-cadherin yielded a Pearson correlation of 0.584 (*P*\<0.1) and the correlation for Hes1 and *α*9-integrin a value of 0.771 (*P*\<0.05), thereby suggesting a dependency of Hes1 expression on N-cadherin and *α*9-integrin. This correlation among these proteins confirms, in patients, the aforementioned findings in cultured cells and suggests that Notch activation may also influence the expression of these two adhesion proteins in tumours.

NICD and Hes1 bind to N-cadherin and *α*9-integrin promoters
------------------------------------------------------------

Chromatin immunoprecipitation assay revealed co-immunoprecipitation of both NICD and Hes1 with the N-cadherin and *α*9-integrin promoter sequences. The control IgGs rendered no amplification ([Figure 7](#fig7){ref-type="fig"}). These results pointed to a direct binding of these Notch downstream effectors to the promoter regions of N-cadherin and *α*9-integrin genes.

Discussion
==========

Rhabdomyosarcoma patients with metastatic disease continue to have poor prognosis and the major cause of death in these patients is the formation of distant metastases. The identification of molecular components and mechanisms that control metastasis in RMS may be useful for developing targeted therapies focused on reducing metastasis in this neoplasia. Although the mechanism by which increased N-cadherin expression promotes malignancy is not fully understood, it is thought to promote adhesion of malignant cells to N-cadherin-expressing stromal or endothelial cells, thereby facilitating invasion and migration of tumour cells to distant sites ([@bib31]; [@bib27]). Although several works have demonstrated that N-cadherin expression suffices to promote metastasis in some cancers ([@bib23]; [@bib14]; [@bib17]) and an aberrant N-cadherin expression has been described in RMS ([@bib35]), no previous publications have shown the importance of N-cadherin for RMS invasiveness. Herein, a central role of N-cadherin in RMS cell adhesion and motility is demonstrated; furthermore, a new mechanism of N-cadherin induction, mediated by Notch pathway activation, is also proposed. Likewise, *α*9-integrin -- forming a heterodimer with *β*1-integrin -- has previously been implicated in processes, such as cell migration, involving dynamic interaction among cells and their microenvironment ([@bib13]; [@bib24]). However, its possible role in RMS remains unknown. Therefore, this work represents the first description of a pro-invasive role of *α*9-integrin in RMS.

We and others recently implicated the Notch pathway in paediatric sarcoma motility and invasiveness ([@bib43]; [@bib29]); however, the molecular connection between the Notch pathway and the process that leads to cell adhesion remains largely obscure. A previous work described the requirement of Notch activation in the epithelial-to-mesenchymal transition of epithelial cells, which finally rendered a disassembly of E-cadherin junctions, thereby permitting an increase in cell motility ([@bib40]). The results herein presented point to the existence of a Notch-mediated mechanism able to positively modulate the expression of adhesion proteins, such as N-cadherin and *α*9-integrin, which may drive motility and invasiveness in neoplasic cells, thereby permitting cancer progression. The three cell lines studied belong to different RMS subtypes and are known to have great biological differences. Two contain PAX/FOXO1 translocations and one bears no translocation. The fact that we consistently found a relationship between Notch and N-cadherin and *α*9-integrin in such different cell lines suggests that the mechanism here described is a general mechanism in RMS -- and perhaps in other neoplasias -- and not a mere characteristic of a particular RMS subtype. Therefore, Notch-controlled changes in the levels of proteins implicated in tumour cell spread, such as a downregulation of E-cadherin in epithelial tumours ([@bib40]) and an upregulation of N-cadherin and *α*9-integrin in a mesenchymal tumour such as RMS, support the role of Notch as an upstream key signalling pathway in the control of cancer dissemination. Furthermore, the promoter-binding study, herein provided, pointed to a direct interaction of Hes1 and NICD to N-cadherin and *α*9-integrin gene regulatory regions. NICD and Hes1 are known to be proteins able to bind directly (Hes1) or indirectly (NICD) to DNA, thereby influencing gene transcription. The binding of NICD to the N-cadherin and *α*9-integrin promoter regions strongly suggests a role in their transcriptional activation, as NICD is an archetypal transcriptional activator. On the other hand, Hes1 is a known transcriptional repressor; however, it may also act as a transcriptional activator of certain genes ([@bib39]). It is not clear whether Hes1 can exert a repressive or activating role in the promoters of the two genes included in this study. It is also conceivable that the relative amounts of both NICD and Hes1 may cooperatively regulate -- inducing or repressing, depending on their relative proportion -- the expression of the N-cadherin and *α*9-integrin genes.

The use of pharmacological Notch pathway inhibitors, such as GSIs, has been proposed as a therapeutic alternative in several cancers, focused essentially on reducing cell proliferation. Several GSIs have been actively studied as potential inhibitors of the generation of the *β*-amyloid peptide associated with Alzheimer\'s disease ([@bib33]). More recently, some GSIs have begun to be studied in phase I--II trials for patients with advanced breast cancer and acute T-cell leukaemias ([@bib7]; [@bib16]). Beyond the use of GSIs as anti-proliferation agents, the results of our experiments point to GSIs as compounds able to reduce the invasive features of tumour cells and, therefore, suitable for use in the fight against metastasis.

Taken together, the results of this work reveal that the Notch pathway has a significant role in the regulation of N-cadherin and *α*9-integrin expression in RMS and, therefore, the Notch pathway should be considered a key regulator of the mechanisms, such as cell motility and invasiveness, which lead to tumour progression. Hence, Notch-inhibiting molecules can be considered as possible therapeutic agents against metastasis. Furthermore, the importance of N-cadherin and *α*9-integrin as players directly involved in cell attachment, migration and invasiveness in RMS is also demonstrated, consequently pointing to these proteins as new candidates for target-specific therapies focused on reducing metastasis in this neoplasia.
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![Cell adhesion to fibronectin- or collagen-coated plates. Images showing a representative field of attached cells for each cell line in the presence (GSI) or absence (DMSO) of *γ*-secretase inhibitor and plots representing the quantification of cells attached to fibronectin- (**A**) or collagen-coated (**B**) plates. All samples were evaluated in triplicate. Student\'s *t*-test significance: \**P*\<0.05, \*\**P*\<0.005.](bjc2012411f1){#fig1}

![Pharmacological inhibition of Notch signalling significantly reduced N-cadherin and *α*9-integrin expression. (**A**) Complementary DNA (cDNA) expression microarray showing the relative levels of *α*9-integrin (ITGA9), N-cadherin (N-Cad) and Hes1 expression in GSI-treated samples (GSI) compared with the control (DMSO). (**B**) Panel of western blots showing the effects of GSI on full-length N-cadherin (N-Cad/FL) and CTF2 fragment, *α*9-integrin (ITGA9), NICD and Hes1 levels compared with untreated samples (DMSO). Alpha-tubulin was used as a loading control. Below the western blot composition, a plot depicting densitometric analysis of each band of the western blot. (**C**) Relative mRNA levels evaluated by quantitative PCR in the presence (GSI) or absence (DMSO) of *γ*-secretase inhibitor. Neuronal cadherin, *α*9-integrin and Hes1 mRNA levels were evaluated in triplicate. Student\'s *t*-test significance: \**P*\<0.05, \*\**P*\<0.005.](bjc2012411f2){#fig2}

![Genetic modifications of the Notch pathway influenced N-cadherin and *α*9-integrin expression. Western blots showing the concomitant variations of Notch pathway activation (NICD and Hes1) and N-cadherin (N-Cad/FL and CTF2) and *α*9-integrin (ITGA9) expression in RMS cells transfected with Delta (**A**) or dnMAML1 (**B**). Below each western blot composition, a plot depicting densitometric analysis of each band of the western blot. The variations associated with genetic modification of the Notch pathway (Delta and MAML1 transfections) observed in protein are also seen in the mRNAs of N-cadherin, *α*9-integrin and Hes1 determined by quantitative PCR (**C**). All RNA measurements were taken in triplicate. Student\'s *t*-test significance: \**P*\<0.05, \*\**P*\<0.005.](bjc2012411f3){#fig3}

![N-cadherin and *α*9-integrin immunocytochemistry. Immunocytochemistry with anti-Hes1 and N-cadherin (N-Cad) antibodies (**A**) or Hes1 and *α*9-integrin (ITGA9) antibodies (**B**) in cells transfected with Delta or control vector (CTRL). Staining was as follows: Hes1 (green), N-cadherin and *α*9-integrin (red) and nuclei (blue). (**C**) Relative fluorescence quantification for Hes1, N-cadherin and *α*9-integrin. Student\'s *t*-test significance: \**P*\<0.05.](bjc2012411f4){#fig4}

![Anti-N-cadherin- and anti-*α*9-integrin-blocking antibodies reduced invasive properties induced by Notch activation. Three RMS cell lines were transfected with the constructions indicated below the bottom of each bar (pCDNA, Delta) in the presence (+) or absence (−) of either N-cadherin-blocking antibody (N-Cad Ab) or *α*9-integrin-blocking antibody (*α*9-ITG Ab) as indicated in the figure. (**A**) Adhesion assay on fibronectin-coated plates. The percentage of cells attached was quantified per cell line and condition. (**B**) Wound-healing assay. All bars indicate the healing velocity of each cell line, transfection and treatment (**C**) Matrigel/Transwell assay. Invasiveness is represented as a percentage of cells in the lower compartment, compared with the control. The three assays were performed in three independent wells per cell line and condition. Student\'s *t*-test significance: \**P*\<0.05.](bjc2012411f5){#fig5}

![The expression of Hes1, N-cadherin and *α*9-integrin correlate in archival RMS tumour samples. (**A**) Representative sections of three patients (34, 37 and 41) stained with anti-Hes1, N-Cad and *α*9-integrin antibodies. (**B** and **C**) Plots depicting the correlations between Hes1 and both N-cadherin and *α*9-integrin semiquantitative scores. Pearson correlation value and significance are shown in the upper left corner in each plot.](bjc2012411f6){#fig6}

![Binding of NICD and Hes1 to N-cadherin and *α*9-integrin promoters. Lysates from RH30 cells were analysed by ChIP assay using specific antibodies against Hes1, NICD and rabbit IgG as a control. Immunoprecipitated chromatin was amplified by PCR using N-cadherin and *α*9-integrin promoter region-specific primers. IgG: negative control rabbit IgG; Input: 5% of the sonicated cell lysate used for IP; H~2~O: PCR negative control; M: 100 bp DNA ladder.](bjc2012411f7){#fig7}
